Surprisingly, despite a generally favorable prognosis of women with metastatic HR-positive/ERBB2-negative breast cancer with median survival now exceeding 5 years,33 survival among that subgroup in our study was relatively short. Here, ERBB2 is linked to breast carcinoma.